Results for: C_TS4CO_2023日本語出題内容 🐇 C_TS4CO_2023日本語全真模擬試験 🥗 C_TS4CO_2023日本語試験勉強書 🤟 ➡ www.goshiken.com ️⬅️で✔ C_TS4CO_2023日本語 ️✔️を検索して、無料で簡単にダウンロードできますC_TS4CO_2023日本語試験参考書

Managing patients with severe Alzheimer disease

January 27, 2009

…antipsychotics for patients with severe agitation, aggression and psychosis, according to the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (Herrmann & Gauthier. Can Med Assoc J 2008;179:1279-1287; free text at www.cmaj.ca/cgi/content/full/179/12/1279. See also Patterson et al. Can Med Assoc J 1999;160:1738-1742). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email ad…

Anticholinergic drug use may be associated with cognitive decline

December 10, 2008

…REPORT FROM THE 133rd AMERICAN NEUROLOGICAL ASSOCIATION MEETING – Anticholinergic agents (e.g. tolterodine, oxybutynin) are frequently prescribed in the elderly but may produce an accelerated cognitive decline, according to a U.S. study (Janos et al. Abstract T-35). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

MoCA useful to assess cognitive function in Parkinson’s disease

December 10, 2008

…REPORT FROM THE 133rd AMERICAN NEUROLOGICAL ASSOCIATION MEETING – The Montreal Cognitive Assessment (MoCA) appears to be more sensitive than the Mini Mental State Examination (MMSE) in detecting cognitive changes and may be useful in patients with Parkinson’s disease. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Emerging MS therapies – Part II

November 25, 2008

REPORT FROM THE WORLD CONGRESS ON TREATMENT AND RESEARCH IN MS – A number of new therapies are currently in development for the treatment of MS. In part two of this two-part article, we summarize the most recent data presented at the World Congress. (See Emerging MS therapies – Part I for information on cladribine, teriflunomide and fingolimod.) Subscribe to read more It takes 30 seconds or login using your email address Please enter the email ad…